SC
GCVRZ

Sophrosyne Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Sophrosyne Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-488,100
Closed -$151K – 92
2014
Q1 		$151K Sell
488,100
-750,898
-61% -$279K 0.13% 67
2013
Q4 		$423K Buy
1,238,998
+664,600
+116% +$803K 0.37% 38
2013
Q3 		$1.16M Buy
+574,398
New +$1.09M 0.77% 35

Other funds holding GCVRZ

WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Sophrosyne Capital's GCVRZ Position: Q2 2014 in Review

Sophrosyne Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2014, closing a stake of 488,100 shares — an estimated $151K sold.

Sophrosyne Capital first reported a position in GCVRZ in Q3 2013 and held it in 3 quarters. The position peaked at $1.16M in Q3 2013. 124 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2014.

  • Sophrosyne Capital reported no remaining Sanofi Contingent Value Rights position as of Q2 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 488,100 Sanofi Contingent Value Rights shares in Q2 2014, an estimated $151K.
  • Sophrosyne Capital first reported a position in Sanofi Contingent Value Rights in Q3 2013 and held it in 3 quarters.
  • Sophrosyne Capital's Sanofi Contingent Value Rights position peaked at $1.16M in Q3 2013.
  • 124 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2014.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.